Resultados: 4

    The management of myelofibrosis: a British Society for Haematology guideline

    Br. j. haematol; 204 (1), 2024
    This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015 These guidelines aim to pro-vide healthcare professionals with clear guidance on stratified management for primary myelofibrosis (PMF)...

    European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

    Eur. j. endocrinol; 178 (1), 2018
    BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with meta...

    Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

    Can. j. cardiol; 32 (7), 2016
    Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This ...

    SIE, SIES, GITMO revised guidelines for the management offollicular lymphoma

    Am. j. hematol; 90 (1), 2005
    By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...